4.55
-0.23(-4.81%)
Currency In USD
| Previous Close | 4.78 |
| Open | 4.51 |
| Day High | 4.76 |
| Day Low | 4.42 |
| 52-Week High | 13.2 |
| 52-Week Low | 4.42 |
| Volume | 28,380 |
| Average Volume | 24,134 |
| Market Cap | 8.71M |
| PE | -0.17 |
| EPS | -26.42 |
| Moving Average 50 Days | 5.47 |
| Moving Average 200 Days | 6.73 |
| Change | -0.23 |
If you invested $1000 in Bolt Biotherapeutics, Inc. (BOLT) since IPO date, it would be worth $7.08 as of November 08, 2025 at a share price of $4.55. Whereas If you bought $1000 worth of Bolt Biotherapeutics, Inc. (BOLT) shares 3 years ago, it would be worth $176.36 as of November 08, 2025 at a share price of $4.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CSE Bulletin: Consolidation - Bolt Metals Corp. (BOLT)
Newsfile
Oct 20, 2025 4:58 PM GMT
Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Bolt Metals Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty five (25) pre-
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
GlobeNewswire Inc.
Oct 01, 2025 8:05 PM GMT
Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the tre